An experimental nanogel given in two intravenous injections improved memory-related behavior and increased neuronal markers in mice engineered to develop features of Alzheimer’s disease. The result is intriguing because the treatment was designed to turn brain-supporting astrocytes into neurons. It is not evidence that Alzheimer’s disease has been reversed in people, however, and several central questions—including where the apparent new neurons came from and whether they joined working brain circuits—remain unanswered.

Key facts

  • The researchers tested a system called TN-PTBP1 Nano-ERASER in human cell cultures, human brain organoids and 5XFAD mice.
  • Eight-month-old mice received two intravenous injections eight days apart.
  • Treated mice performed better in nesting and spatial-memory tests and showed higher neuronal density.
  • The experiments used small animal groups and have not progressed to primates or human trials.

The experiment tried to replace neurons using cells already in the brain

Alzheimer’s disease gradually damages neurons and the connections that support memory. Most experimental treatments try to slow that damage or remove disease-associated proteins. This study pursued a more ambitious question: could some lost neurons be replaced by reprogramming astrocytes, abundant cells that normally support and regulate the brain?

The Nano-ERASER nanogel carried an antibody against PTBP1, an RNA-binding protein that helps astrocytes maintain their cellular identity. After crossing the blood–brain barrier, the carrier was designed to release the antibody inside astrocytes. The antibody then recruited a cellular protein-disposal mechanism called Trim-Away, temporarily reducing PTBP1.

Lower PTBP1 levels were associated with the appearance of neuron-like cells. Unlike gene-editing systems such as CRISPR, the approach did not alter DNA, and PTBP1 levels could recover after treatment. That reversibility could be useful, but the duration and safety of the effect still need to be established.

What happened in cells, organoids and mice

In cultured human astrocytes, treated cells developed neuronal shapes and markers. Electrical recordings indicated that the resulting cells could fire and participate in synchronized activity.

The researchers then used human brain organoids—small laboratory-grown models containing neurons and astrocytes. After the organoids were exposed to human serum to reproduce selected features associated with sporadic Alzheimer’s disease, Nano-ERASER treatment increased mature-neuron markers and restored neuronal density toward the level in control organoids. Organoids can reveal cellular mechanisms, but they are not miniature human brains and cannot reproduce the full disease.

For the animal experiment, the team used 5XFAD mice, which carry human gene variants that cause rapid amyloid accumulation and cognitive impairment. The eight-month-old mice received two injections separated by eight days. Tissue analysis later found reduced PTBP1 in astrocytes, more immature- and mature-neuron markers, higher neuronal density, lower inflammatory molecules and a reduced amyloid burden.

The behavioral results moved in the same direction. Treated mice progressively recovered their ability to build nests. In the Morris water maze, they located a hidden platform more quickly and showed better memory for its position. Those tests support improved performance in this model; they do not establish recovery from human dementia.

Why the result is promising—and why caution is essential

A treatment that could safely rebuild damaged neural circuits would address something current Alzheimer’s medicines do not do. But the largest leap in this story is also the least settled: showing that astrocytes became new neurons inside a living brain and that those neurons integrated into functional circuits.

The paper did not fully trace the origin of every apparent new neuron. It also did not establish how the nanoparticles were distributed across all brain-cell types, directly analyze microglial states, or show how long the changes would last. The behavioral experiments involved small groups of mice, and 5XFAD animals reproduce selected Alzheimer-like features rather than the complex, predominantly sporadic disease seen in most people.

PTBP1-based cell conversion has also been disputed in earlier neuroscience research, making independent replication and rigorous cell-lineage tracing especially important. The researchers identify long-term safety testing, dose optimization, circuit-integration studies and experiments in non-human primates as necessary next steps.

Bottom line: two injections produced notable cellular and behavioral improvements in an Alzheimer’s mouse model. The study opens a regenerative research path; it does not provide a treatment that patients can receive.

Sources

  1. Wang et al., “Reverse the progression of Alzheimer’s disease through Nano-ERASER-based adult neuroregeneration,” Cell Biomaterials (2026).
  2. Agencia SINC, research summary and interview with senior author Peisheng Xu.
  3. Chen et al., independent study examining limitations of glia-to-neuron reprogramming claims.

Editorial disclosure: The lead image is a concept illustration, not a photograph of the experiment. SciQuest received no payment to cover this study. To report a possible error, contact SciQuest.